The global cardiovascular therapeutic drug market reached $140.7 billion in 2009 and is expected to grow by a compound annual growth rate (CAGR) of 2.7 percent to $144.5 billion in 2010, according to an Oct. 6 report published by Companies and Markets.
The hypertension sector will increase from $64.9 billion in 2009 to $65.3 billion in 2010; however, the sector will likely decrease to $53.7 billion through 2015, according to the report.
Additionally, there was a reported $33 billion in sales of drugs for hyperlipidemia in 2009, driven by sales of atorvastatin (Lipitor,Pfizer) and rosuvastatin (Crestor, AstraZeneca). Due to patent expiries of Lipitor and other high-grossing drugs in the sector, researchers estimate that the segment will shrink by 4.3 percent in 2015 to $26 billion.
The Companies and Markets report depicts an analysis of CV therapies and forecasts global market growth through 2015.